Skip to content


Emgality (galcanezumab) is an antibody pharmaceutical. Galcanezumab was first approved as Emgality on 2018-09-27. It is used to treat cluster headache in the USA. It has been approved in Europe to treat migraine disorders. The pharmaceutical is active against calcitonin; calcitonin gene-related peptide 1.
Trade Name Emgality
Common Name Galcanezumab
Indication cluster headache, migraine disorders
Drug Class Monoclonal antibodies: humanized, neural indications
Get full access now